Hutchison China MediTech’s (Chi-Med’s) noteworthy achievements in FY18 include the landmark approval and launch of Elunate (fruquintinib) in China in 3L mCRC; the continued maturation of the tyrosine kinase inhibitor (TKI) pipeline with multiple assets either in, or approaching, China or Global registrational trials; and significant investment in building the US infrastructure to support the Global Innovation pipeline. 2019 should bring further progress, with a steady stream of clinical catalysts. Next up will be savolitinib NSCLC data at AACR (March 29-April 3). We continue to value Chi-Med at $33.49/ADS or £51.52/share.
21 Mar 2019
Bringing Global Innovation and China Oncology into focus
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Bringing Global Innovation and China Oncology into focus
HUTCHMED (China) Limited (HCM:LON) | 267 -2.7 (-0.4%) | Mkt Cap: 2,326m
- Published:
21 Mar 2019 -
Author:
Franc Gregori -
Pages:
8
Hutchison China MediTech’s (Chi-Med’s) noteworthy achievements in FY18 include the landmark approval and launch of Elunate (fruquintinib) in China in 3L mCRC; the continued maturation of the tyrosine kinase inhibitor (TKI) pipeline with multiple assets either in, or approaching, China or Global registrational trials; and significant investment in building the US infrastructure to support the Global Innovation pipeline. 2019 should bring further progress, with a steady stream of clinical catalysts. Next up will be savolitinib NSCLC data at AACR (March 29-April 3). We continue to value Chi-Med at $33.49/ADS or £51.52/share.